Pioneering a New World of Medicine
with Bubbles and Ultrasound
In solid tumors such as pancreatic cancer and in central nervous system disorders, biological barriers remain a major obstacle to effective drug delivery.
Wellthera has developed BUS-DDS (Bubble Ultrasound-mediated Drug Delivery System), an innovative platform that combines therapeutic microbubbles with low-intensity ultrasound.
BUS-DDS enables drugs to cross previously inaccessible biological barriers, expanding the therapeutic potential of both existing and novel medicines and creating new treatment opportunities.
Stay up to date with our latest announcements, research activities, and events.
WellThera to Exhibit, Participate in Partnering Meetings, and Present at BioJapan 2026
WellThera Co., Ltd. will exhibit at BioJapan 2026, to be held at Pacifico Yokohama from October 7 (Wed) to 9 (Fri), 2026. During the event,
Notice of Participation and Presentation at THE 1st CHINA PHARMACEUTICAL INNOVATION CONFERENCE (CPIC 2026)
WellThera Co., Ltd. will participate in THE 1st CHINA PHARMACEUTICAL INNOVATION CONFERENCE (CPIC 2026), which will be held in Shanghai, China, from July 22 to
[Video Release] Introduction of BUS-DDS in TEDx Talk
We are pleased to announce that the following talk delivered at TEDxTeikyoU has been published on the TEDxTalks YouTube channel: “Theranostic bubbles & US deliver
Wellthera is a spin-off from Teikyo University, developing proprietary technologies based on therapeutic microbubbles and ultrasound.
With a strong focus on clinical translation, we are building a platform that advances drug delivery and supports the development of next-generation therapies.
We welcome inquiries about collaborative research, business partnerships, and investor relations.